The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the pharmacokinetic and safety characteristics of
European Taxotere® and American Taxotere® with Hospira Docetaxel injection in patients with
cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer